iwCLL 2017 | Which CLL patients would benefit from intensive therapy?
Inhye Ahn, MD from the National Institutes of Health, Bethesda, MD discusses who would benefit from intensive therapy, which is the combination of ibrutinib and fludarabine. She explains how some patients who do not have complex cytogenetic abnormalities or deletion of 17p could actually reach stable disease for up to five years on just the single agent ibrutinib. Her work now is focussed on trying to identify those patients who would require the combined intensive therapy. This interview was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY
Get great new content delivered to your inboxSign up